280115-99-3

Basic information

• Product Name: tert-Butyl 4-(chlorocarbonyl)-piperidine-1-carboxylate
• Synonyms: tert-Butyl 4-(chlorocarbonyl)-piperidine-1-carboxylate
• CAS NO: 280115-99-3
• Molecular Formula: C₁₁H₁₈ClNO₃
• Molecular Weight: 247.71852
• Mol File: 280115-99-3.mol
• Article Data: 36

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-Butyl 4-(chlorocarbonyl)-piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(chlorocarbonyl)-piperidine-1-carboxylate(280115-99-3)
• EPA Substance Registry System: tert-Butyl 4-(chlorocarbonyl)-piperidine-1-carboxylate(280115-99-3)

Safety Data

• Hazardous Substances Data: 280115-99-3(Hazardous Substances Data)

Upstream product

• 79-37-8 oxalyl dichloride 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 498-94-2 isonipecotic acid 
• 383865-57-4 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine 
• 216866-88-5 1-(tert-butoxycarbonyl)-4-(6-chloronaphthalene-2-sulfonyl)piperazine 

Downstream Products

• 139290-71-4 4-(2,3-Dimethoxybenzoyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 
• 139290-72-5 (2,3-dimethoxyphenyl)(piperidin-4-yl)methanone 
• 243640-26-8 tert-butyl 4-((2,3-dimethoxyphenyl)(hydroxy)methyl)piperidine-1-carboxylate 
• 140235-25-2 (+/-)-α-(2,3-dimethoxyphenyl)-4-piperidinemethanol 
• 293744-33-9 tert-butyl 4-{[(benzyl)(2-bromo-4-nitrophenyl)amino]carbonyl}piperidine-1-carboxylate 
• 293744-32-8 tert-butyl 4-{[(benzyl)(2-bromo-4-methylphenyl)amino]carbonyl}piperidine-1-carboxylate 
• 293744-35-1 tert-butyl 1-benzyl-1,2-dihydro-5-methyl-2-oxospiro[3H-indole-3,4'-piperidine]-1'-carboxylate 
• 293744-31-7 tert-butyl 4-{[(benzyl)(2-bromophenyl)amino]carbonyl}piperidine-1-carboxylate 
• 293744-34-0 tert-butyl 1-benzyl-1,2-dihydro-2-oxospiro[3H-indole-3,4'-piperidine]-1'-carboxylate 
• 293744-26-0 tert-butyl 4-{[(2-bromophenyl)amino]carbonyl}piperidine-1-carboxylate 
• 293744-27-1 tert-butyl 4-{[(2-bromo-4-methylphenyl)amino]carbonyl}piperidine-1-carboxylate 
• 1076227-96-7 (3S,4S)-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluoro-2-methylphenyl)-1-[(1-glycoloylpiperidin-4-yl)carbonyl]-N-methylpiperidine-4-carboxamide 
• 1076227-97-8 (3S,4S)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-3-(4-fluoro-2-methylphenyl)-1-[(1-glycoloylpiperidin-4-yl)carbonyl]-N-methylpiperidine-4-carboxamide 

Relevant articles and documents

Synthesis and biological evaluation of 3-(piperidin-4-yl)isoxazolo[4,5-d]pyrimidine derivatives as novel PI3Kδ inhibitors

An efficient synthesis of novel 3-(piperidin-4-yl)isoxazolo[4,5-d]pyrimidine scaffold has been designed and deveopled. A series of 5-phenylurea derivatives was synthesized using this method. Their cytotoxic activities against breast cancer cell line BT-474 were evaluated by CCK-8 assay. Most of them showed potent anti-proliferative activities, of which compound 20 and 21 exhibited IC50s of 1.565 μmol/L and 1.311 μmol/L, respectively. Furthermore, compound 20 and 21 also showed potent inhibitory activities against PI3Kδ with IC50s of 0.286 μmol/L and 0.452 μmol/L, respectively. These results indicate that these 3-(piperidin-4-yl)isoxazolo[4,5-d]pyrimidine derivatives are novel antitumor agents through the inhibition of PI3Kδ.

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound having a histone deacetylase 6 (HDAC6) inhibitory activity, an isomer thereof or a pharmaceutically acceptable salt thereof, the use thereof for preparing a therapeutic medicament; a pharmaceutical composition containing the same, and a treatment method using the composition; and a preparation method thereof. The novel compound, the isomer thereof, or the pharmaceutically acceptable salt thereof according to the present invention has the HDAC6 inhibitory activity, which is effective in the prevention or treatment of HDAC6-mediated diseases including cancer, inflammatory diseases, autoimmune diseases, neurological or neurodegenerative diseases.

Small Molecule Inhibitors of the BfrB-Bfd Interaction Decrease Pseudomonas aeruginosa Fitness and Potentiate Fluoroquinolone Activity

The iron storage protein bacterioferritin (BfrB) is central to bacterial iron homeostasis. The mobilization of iron from BfrB, which requires binding by a cognate ferredoxin (Bfd), is essential to the regulation of cytosolic iron levels in P. aeruginosa. This paper describes the structure-guided development of small molecule inhibitors of the BfrB-Bfd protein-protein interaction. The process was initiated by screening a fragment library and followed by obtaining the structure of a fragment hit bound to BfrB. The structural insights were used to develop a series of 4-(benzylamino)- A nd 4-((3-phenylpropyl)amino)-isoindoline-1,3-dione analogs that selectively bind BfrB at the Bfd binding site. Challenging P. aeruginosa cells with the 4-substituted isoindoline analogs revealed a dose-dependent growth phenotype. Further investigation determined that the analogs elicit a pyoverdin hyperproduction phenotype that is consistent with blockade of the BfrB-Bfd interaction and ensuing irreversible accumulation of iron in BfrB, with concomitant depletion of iron in the cytosol. The irreversible accumulation of iron in BfrB prompted by the 4-substituted isoindoline analogs was confirmed by visualization of BfrB-iron in P. aeruginosa cell lysates separated on native PAGE gels and stained for iron with Ferene S. Challenging P. aeruginosa cultures with a combination of commercial fluoroquinolone and our isoindoline analogs results in significantly lower cell survival relative to treatment with either antibiotic or analog alone. Collectively, these findings furnish proof of concept for the usefulness of small molecule probes designed to dysregulate bacterial iron homeostasis by targeting a protein-protein interaction pivotal for iron storage in the bacterial cell.